Latest Breaking News On - Jordi rodon - Page 1 : comparemela.com

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

STC-15 is the first METTL3 inhibitor to enter clinical development Clinical data will include safety, pharmacology, target modulation, and clinical activity CAMBRIDGE, England, May

United statesSan antonioUnited kingdomJustin moserJordi rodon ahnertKyriakos papadopoulosJosefin beate holzHonorhealth research instituteAmerican society of clinical oncologyTherapeutics ltdStorm therapeutics ltdIp groupUtokyo innovation platform co ltdFast track initiativeJustin moser at honorhealth research instituteSeroba life sciences

MD Anderson Research Highlights for May 8, 2024

MD Anderson Research Highlights for May 8, 2024
newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.

United statesChris broseyTraver hartJordi rodonJonathan kurieAnn kloppAmerican association for cancer researchNature communicationsCancer centerResearch highlightsAmerican associationCancer researchAnnual meetingFunda meric bernstamJohn tainerNature chemical

AACR: Trio of studies highlights promising early results with new cancer therapies and targets

Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Resear

United statesKlus pharmaTimothy yapJordi rodonNational cancer instituteBristol myers squibb companyExperimental therapeutics clinical trials networkAmerican association for cancer researchNational institutes of healthAndrew sabin family fellowship programAstrazeneca pharmaceuticalsNational cancer institute therapy evaluation programUniversity of texas md anderson cancer centerMerck coDevelopment agreementCancer center

Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers

Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.

United statesKlus pharmaJordi rodonTimothy yapMerck coDevelopment agreementAndrew sabin family fellowship programAmerican association for cancer researchUniversity of texas md anderson cancer centerExperimental therapeutics clinical trials networkBristol myers squibb companyNational cancer institute therapy evaluation programNational cancer instituteAstrazeneca pharmaceuticalsNational institutes of healthManderson cancer

AACR: Early Results Show Promise in New Cancer Treatments

AACR: Early Results Show Promise in New Cancer Treatments
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesTimothy yapKlus pharmaJordi rodonDevelopment agreementMerck coBristol myers squibb companyAstrazeneca pharmaceuticalsNational cancer instituteNational institutes of healthAndrew sabin family fellowship programAmerican association for cancer researchUniversity of texas md anderson cancer centerExperimental therapeutics clinical trials networkCancer centerAmerican association